ArticleNucleic acids research2016
CancerResource--updated database of cancer-relevant proteins, mutations and interacting drugs.
Article in Nucleic acids research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 40 citations in OpenAlex.
- The role and application of bioinformatics techniques and tools in drug discovery.Frontiers in pharmacology · 2025Review
- Review
- Bioinformatics roadmap for therapy selection in cancer genomics.Molecular oncology · 2022Review
- A critical review of datasets and computational suites for improving cancer theranostics and biomarker discovery.Medical oncology (Northwood, London, England) · 2022Review
- Non-swarm-based computational approach for mining cancer drug target modules in protein interaction network.Medical & biological engineering & computing · 2022Article
- Biomolecule and Bioentity Interaction Databases in Systems Biology: A Comprehensive Review.Biomolecules · 2021Review
- Luminescent Analysis of Blood Serum for Diagnostics of Pathological and Pre-Pathological States of Cancer Patients.Journal of fluorescence · 2021Article
- Light-Responsive Micelles Loaded With Doxorubicin for Osteosarcoma Suppression.Frontiers in pharmacology · 2021Article
- Towards the routine use of in silico screenings for drug discovery using metabolic modelling.Biochemical Society transactions · 2020Review
- Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics.Nucleic acids research · 2020Article
- Free Accessible Databases as a Source of Information about Food Components and Other Compounds with Anticancer Activity⁻Brief Review.Molecules (Basel, Switzerland) · 2019Review
- Review
- GDA, a web-based tool for Genomics and Drugs integrated analysis.Nucleic acids research · 2018Article
- PanDrugs: a novel method to prioritize anticancer drug treatments according to individual genomic data.Genome medicine · 2018Article
- Therapeutic target database update 2018: enriched resource for facilitating bench-to-clinic research of targeted therapeutics.Nucleic acids research · 2018Article
- Bioinformatics and Drug Discovery.Current topics in medicinal chemistry · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Here, we present an updated version of CancerResource, freely available without registration at http://bioinformatics.charite.de/care. With upcoming information on target expression and mutations in patients' tumors, the need for systems supporting decisions on individual therapy is growing. This knowledge is based on numerous, experimentally validated drug-target interactions and supporting analyses such as measuring changes in gene expression using microarrays and HTS-efforts on cell lines. To enable a better overview about similar drug-target data and supporting information, a series of novel information connections are established and made available as described in the following. CancerResource contains about 91,000 drug-target relations, more than 2000 cancer cell lines and drug sensitivity data for about 50,000 drugs. CancerResource enables the capability of uploading external expression and mutation data and comparing them to the database's cell lines. Target genes and compounds are projected onto cancer-related pathways to get a better overview about how drug-target interactions benefit the treatment of cancer. Features like cellular fingerprints comprising of mutations, expression values and drug-sensitivity data can promote the understanding of genotype to drug sensitivity associations. Ultimately, these profiles can also be used to determine the most effective drug treatment for a cancer cell line most similar to a patient's tumor cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.